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2ABSTRACT 
Inflammasomes regulate microglial caspase-1 activation and subsequent neuroinflammatory 
processes in brain pathology.  In the present study, we have identified inflammasomes 
causing caspase-1 activation following stimulation of microglia with lysophosphatidylcholine 
(LPC), a proinflammatory lipid generated under pathological conditions in the brain.  LPC-
induced caspase-1 activation in microglia was found to depend on LPS prestimulation, 
inflammasome NLRP3 and adaptor molecule ASC.  Furthermore, knockdown of 
inflammasome NLRC4 inhibited LPC-stimulated caspase-1 activity in microglia, suggesting 
the requirement of two inflammasomes for optimal caspase-1 activity.  
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1. Introduction 
Caspase-1 has been considered as a potential therapeutic target in a variety of 
neurological diseases (Vezzani et al., 2010; Walsh et al., 2014; Song et al., 2017).  It converts 
biologically inactive precursors of the proinflammatory cytokines interleukin (IL)-1β, IL-18 
and IL-33 into their mature, biologically active forms, which play a pivotal role in promoting 
neuroinflammatory processes (Eder, 2009; Garlanda et al., 2013).  Mechanisms underlying 
caspase-1 activation in microglia are not completely understood.  Multiple pathways can lead 
to caspase-1 activation in microglia, while intracellular protein complexes called 
inflammasomes are major components of the activation cascade of caspase-1 (Walsh et al., 
2014; Song et al., 2017).  
Lysophosphatidylcholine (LPC) is a proinflammatory lipid, which is released from 
apoptotic cells or produced under inflammatory or ischemic conditions in the brain as a result 
of enhanced phospholipase A2 activity (Farooqui and Harrocks, 2006; Drzazga et al., 2014).  
3LPC can cause microglial recruitment during brain development (Xu et al., 2016) and 
microglial activation in brain pathology (Inose et al., 2015).  We have previously 
demonstrated that LPC induces caspase-1 activation in microglia (Stock et al., 2006), which 
depends on Na+ influx, reactive oxygen species production and intact lipid rafts (Schilling 
and Eder, 2010, 2011).  Here, we have extended our studies and identified inflammasomes 
regulating LPC-stimulated caspase-1 activity in microglia.  
2. Materials and methods
2.1. Materials
The following drugs were used in this study: synthetic L--lysophosphatidylcholine 
(LPC), palmitoyl (16:0); lipopolysaccharide (LPS) from E. coli 055:B5 (both from Sigma-
Aldrich, Germany).  Stock solutions of 30 mM LPC and 1 mg/ml LPS were prepared in H2O. 
2.2. Cells 
All experiments were performed on the microglial cell line BV-2.  Cells were cultured 
permanently in DMEM supplemented with 10% FCS and 2 mM L-glutamine as described 
previously (Stock et al., 2006).  Cells were split twice a week, and were plated on glass 
coverslips at a density of 1x105/ml for subsequent experiments.  During experiments, cells were 
maintained in an extracellular solution containing (in mM): NaCl, 130; KCl, 5; CaCl2, 2; MgCl2, 
1; HEPES, 10; D-glucose, 10 (pH 7.4) as described previously (Stock et al., 2006; Schilling et 
al., 2010, 2011).
2.3. siRNA-induced knockdown of NLRC4, NLRP3 and ASC 
One day before transfection with siRNA, BV-2 microglial cells were seeded in 35 mm 
petri dishes at a density of 3x105/ml and maintained in DMEM supplemented with 10% FCS 
4and 2 mM L-glutamine.  The siRNAs for targeting the murine mRNAs of ASC (NCBI 
accession number NM_023258), NLRC4 (NCBI accession number NM_001033367) and 
NLRP3 (NCBI accession number AY355340) were synthesized by Xeragon/Qiagen (Köln, 
Germany).  Sequences of siRNAs are provided in table 1.  A non-targeting (scrambled) 
siRNA (200 pmoles per dish) was used as a negative control.  To achieve maximum 
efficiencies of gene silencing, cells were transfected with a mixture of 4 different siRNAs, 
each at 50 pmoles per dish.  For this purpose, siRNAs were diluted at a 1:20 volume ratio in 
0.2 ml serum-free DMEM, and the DharmaFECT® transfection reagent (Perbio Science, 
Bonn, Germany) was diluted 1:100 in 0.2 ml serum-free DMEM.  Diluted siRNAs and the 
transfection reagent were combined and kept at room temperature for 20 min to allow 
complex formation.  In the meantime, the culture medium was removed from cells and 
replaced with 1.6 ml fresh DMEM/10% FCS.  The siRNA transfection mixtures (0.4 ml) 
were carefully added to the cells, which were subsequently maintained in a cell culture 
incubator for 24 hours.  
Detection of NLRC4 mRNA, NLRP3 mRNA and ASC mRNA, and their 
downregulation by the corresponding siRNAs were verified by reverse transcription real-time 
PCR.  Total RNA was isolated from cultured cells by the use of TRIzol® reagent (Invitrogen, 
Karlsruhe, Germany) according to the manufacturer’s protocol.  First-strand cDNA synthesis 
was performed with 2 µg of total RNA using oligo(dT) primers and Superscript II reverse 
transcriptase (Invitrogen).  Five percent of the volumes of the reaction products were used for 
quantitative real-time PCR amplification with SYBR® Green PCR Master Mix (Applied 
Biosystems, Foster City, CA).  PCRs were carried out on a GeneAmp5700 thermocycler 
(PerkinElmer Life Sciences) under the following conditions (45 cycles): DNA denaturation 
(15 s) at 94 °C, primer annealing (15 s) and extension of double-stranded DNA at 60 °C (60 
s), detection of SYBR® Green fluorescence at 77 °C (30 s).  PCR primers used for the 
5amplification reactions are listed in table 2.  Threshold cycle (Ct) values for the genes of 
interest were subtracted from Ct values for GAPDH to obtain Ct values.  Differences in 
transcript levels between cells transfected with gene-specific siRNAs and scrambled siRNA, 
respectively, were calculated as Ct(gene of interest) - Ct(scrambled).  Fold increases in 
mRNA levels were obtained according to 2Ct as described in detail previously (Martens et 
al., 2007).  Pretreatment of BV-2 cells with NLRC4 siRNA, NLRP3 siRNA or ASC siRNA 
caused specific reduction in the corresponding mRNA levels by 82.4±15.2%, 56.8±17.6% 
and 78.2±13.4%, respectively (n=3 experiments in each case), compared to cells that had 
been incubated with scrambled siRNA.
2.4. Detection of caspase-1 activity 
Activity of caspase-1 was revealed by FAM-YVAD-FMK (1:150; Immunochemistry 
Technology, Bloomington, USA) using a fluorescence imaging system as described 
previously (Stock et al., 2006; Schilling and Eder, 2010, 2011).  Images of four different 
visual fields for three independent experiments per condition were collected and analyzed.  
Fluorescence intensities of all cells were corrected for background fluorescence.
2.5. Statistics
All data are presented as mean values ± standard error of the mean (SEM) and cell 
numbers are indicated.  The statistical significance of differences between experimental 
groups was evaluated by one-way ANOVA using the SPSS program.  Tukey’s test was used 
for post hoc comparison after confirming homogeneity of variances with Levene’s test.  Data 
were considered to be statistically significant with p<0.05.
63. Results 
3.1. LPC-induced caspase-1 activity requires LPS pretreatment
As demonstrated in Fig. 1A-B, LPC caused substantial increases in caspase-1 activity 
in microglial cells pretreated with 1 µg/ml LPS for 6 h.  In comparison with unstimulated 
control cells, mean fluorescence intensity of microglial cells stimulated with 30 µM LPC for 
1 h was significantly increased to 381.0±7.5% (n=482 cells of 3 independent experiments; 
p<0.001).  In contrast, without LPS pretreatment, mean fluorescence intensities did not differ 
markedly between cells maintained either in the presence or absence of 30 µM LPC for 1 h 
(Fig. 1C-D).  Due to the requirement of LPS pretreatment for LPC-induced caspase-1 
activity, microglial cells were exposed to 1 µg/ml LPS for 6 h prior to LPC stimulation in all 
further experiments.  
3.2. LPC-induced caspase-1 activity requires NLRC4, NLRP3 and ASC  
To further identify mechanisms underlying LPC-stimulated caspase-1 activity, we 
tested whether siRNA-induced knockdown of the inflammasome NLRC4, the inflammasome 
NLRP3 and/or the adaptor protein ASC affect caspase-1 activation in LPC-stimulated 
microglia.  As shown in Fig. 2, control experiments revealed that transfection of cells with 
non-targeting (scrambled) siRNA did not affect LPC-induced caspase-1 activation.  Similar 
to data obtained in microglial cells that had not been exposed to scrambled siRNA (Fig. 1), 
FAM-YVAD-FMK fluorescence intensity of microglia pretreated with scrambled siRNA for 
24 h increased 4-fold (to 384.3±10.0%; n=555 cells of 3 independent experiments; p<0.001) 
in response to stimulation of cells with 30 µM LPC (Fig. 2).  
Following siRNA-induced knockdown of inflammasomes NLRC4 or NLRP3, 
caspase-1 activity was significantly inhibited (Fig. 2), indicating the involvement of both 
inflammasomes in microglial LPC-stimulated caspase-1 activation.  In comparison with LPC-
7stimulated microglia pretreated with scrambled siRNA, mean FAM-YVAD-FMK 
fluorescence intensities were reduced by 69.8±1.0% (n=526 cells of 3 independent 
experiments; p<0.001) or by 35.3±1.6% (n=541 cells of 3 independent experiments; p<0.001) 
in LPC-stimulated microglia pretreated with NLRC4 siRNA or with NLRP3 siRNA, 
respectively.  We additionally tested efficiency and specificity of siRNAs in cells stimulated 
with ATP.  As expected and published by others previously (e.g., Freeman et al., 2017; Song 
et al., 2017), stimulation with 2 mM ATP increased caspase-1 activity in microglia 6-fold (to 
625.8±19.3%, n=562 cells of 3 independent experiments; p<0.001), while NLRP3 siRNA, but 
not NLRC4 siRNA, reduced ATP-induced caspase-1 activity by 80.2±3% (n=546 cells of 3 
independent experiments; p<0.001).  
Furthermore, siRNA knockdown experiments revealed that in addition to the 
inflammasomes NLRC4 and NLRP3, the adaptor protein ASC mainly contributes to caspase-
1 activity in LPC-stimulated microglia.  In LPC-stimulated microglial cells pretreated with 
ASC siRNA, mean FAM-YVAD-FMK fluorescence intensity was reduced by 68.6±1.0% 
(n=542 cells of 3 independent experiments; p<0.001) compared to LPC-stimulated microglial 
cells pretreated with scrambled siRNA for 24 h (Fig. 2).  Independent of pretreatment 
conditions, caspase-1 activity of LPC-stimulated microglia was significantly larger (p<0.001 
in all cases) than that of unstimulated microglia pretreated with scrambled siRNA (Fig. 2).
4. Discussion
In the present study, we have unraveled a novel mechanism of caspase-1 activation in 
microglia, which was triggered by LPC, a recognized damage-associated molecular pattern 
(DAMP) generated in a variety of neurological diseases.  It has been shown previously that 
DAMPs, such as ATP or amyloid-β, cause caspase-1 activity in LPS-pretreated microglia 
exclusively via the inflammasome NLRP3 (Walsh et al., 2017).  The inflammasome NLRC4 
8has only recently been identified in microglia (Jamilloux et al., 2013; Lammerding et al., 
2016; Freeman et al., 2017), and could be activated in cultured microglial cells following 
transfection with the pathogen-associated molecular pattern (PAMP) Legionella pneumonia 
(Jamilloux et al., 2013).  Similar to stimulation with other DAMPs, in LPC-stimulated 
microglial cells, LPS pretreatment was required to trigger caspase-1 activity.  However, in 
contrast to microglial caspase-1 activation induced by other DAMPs, two inflammasomes, 
namely NLRC4 and NLRP3, were found to regulate LPC-induced microglial caspase-1 
activity.  Similar to our findings on microglia, a recent study performed on LPC-stimulated 
astrocytes reported reduced IL-1β secretion from cells of NLRC4 or NLRP3 knockout mice 
(Freeman et al., 2017), suggesting the involvement of both inflammasomes in caspase-1 
activation of astrocytes.  In the past, numerous studies have suggested that the inflammasome 
NLRC4 is predominantly activated by PAMPs (Zhao and Shao, 2015; Vance, 2015).   
What might be the reason for the activation of caspase-1 by LPC in microglia via a 
distinct pathway not used by other DAMPs?  Intriguingly, LPC can exert its effects via 
multiple mechanisms, while it can act both extracellularly and intracellularly.  Extracellular 
effects of LPC are mediated following binding to membrane receptors (Inose et al., 2015; Xu 
et al., 2016) and/or by changing the membrane curvature and subsequent activation of 
mechanosensitive non-selective cation channels (Perozo et al., 2002; Vásquez et al., 2008).  
Furthermore, unlike other DAMPs, LPC is capable of crossing the cell membrane (van der 
Luit et al., 2003).  Thus, it is possible that LPC, like PAMPs, can directly interact 
intracellularly with the NLRC4 inflammasome after its internalization.  In addition, LPC-
induced activation of non-selective cation channels, which mediate Na+ and Ca2+ influx as 
well as K+ efflux, could trigger activation of the inflammasome NLRP3, as has been shown 
for other DAMPs (Walsh et al., 2014; Song et al., 2017).  Thus, LPC stimulation may activate 
9two distinct pathways in parallel, causing simultaneous, but independent, activation of the 
inflammasomes NLRC4 and NLRP3.  
On the other hand, it is also possible that LPC triggers a process similar to that 
recently described for macrophages infected with Salmonella typhimurium, but not other 
PAMPs.  In Salmonella-infected cells, both NLRC4 and NLRP3 inflammasomes form a 
single complex surrounded by the adaptor protein ASC (Broz et al., 2010; Man et al., 2014; 
Qu et al., 2016).  Further work is needed to elucidate the exact mechanism by which LPC 
activates the two inflammasomes and subsequently caspase-1 in microglia. 
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Figure legends
Fig. 1. LPS dependence of LPC-induced caspase-1 activity in microglia.  (A) Microglial cells 
were pretreated with 1 µg/ml LPS for 6 h in DMEM/FCS culture medium, and were 
subsequently kept untreated or treated with 30 µM LPC for 1 h.  Fluorescence intensities 
(mean values±SEM) of LPC-stimulated microglial cells (n=482) were normalized to the 
mean fluorescence intensity of untreated control cells (n=621). (B) Brightfield microscopy 
(upper row) and FAM-YVAD-FMK fluorescence (lower row) images of microglial cells 
either kept untreated (control) or stimulated with 30 µM LPC (LPC) for 1 h following 
prestimulation with 1 µg/ml LPS for 6 h. (C) Microglial cells were kept untreated or treated 
with 30 µM LPC for 1 h without LPS pretreatment.  FAM-YVAD-FMK fluorescence 
intensities (mean values±SEM) of LPC-stimulated microglial cells (n=410) were normalized 
to the mean fluorescence intensity of untreated control cells (n=418). (D) Brightfield 
microscopy (upper row) and FAM-YVAD-FMK fluorescence (lower row) images of 
microglial cells either kept untreated (control) or stimulated with 30 µM LPC (LPC) in the 
absence of LPS. (B, D) Scale bar, 50 µm.
Fig. 2.  Involvement of NLRC4, NLRP3 and ASC in caspase-1 activity in LPC-stimulated 
microglia.  In microglial cells, expression of NLRC4, NLRP3 or ASC was silenced by siRNA 
for 24 h prior to stimulation with 30 µM LPC for 1 h. Fluorescence intensities (mean 
values±SEM) of LPC-stimulated FAM-YVAD-FMK-loaded microglial cells transfected with 
non-targeting (scrambled) siRNA (scr; n=942 untreated cells, n=555 LPC-stimulated cells) or 
NLRC4 siRNA (NLRC4; n=526), NLRP3 siRNA (NLRP3; n=541) or ASC siRNA (ASC; 
n=542) were normalized to the mean fluorescence intensity determined for cells transfected 
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with scrambled siRNA and maintained unstimulated for 1 h.  Prior to LPC stimulation, all 
cells were pretreated with 1µg/ml LPS for 6 hours.  


1Table 1. Sequences of the siRNAs used for gene silencing. 
Target gene (NCBI accession no.) siRNA sequences (sense)
ASC/Pycard (NM_023258) 5’-GCUGCAAACGACUAAAGAAdTdT-3’
5’-GCUACUAUCUGGAGUCGUAdTdT-3’
5’-CAAUGACUGUGCUUAGAGAdTdT-3’
5’-CCAGGCCUUGAAGGAAAUAdTdT-3’
NLRC4 (NM_001033367) 5’-GGGUGAAGAUAUCGACAUAdTdT-3’
5’-GGAUGGGAAUGAAGCUCUAdTdT-3’
5’-GCUUCUCAACAAUCAAGAAdTdT-3’
5’-CGUAUAAAUUCUUUCAUAAdTdT-3’
NLRP3 (AY355340) 5’-CCUCUUAUUUGGAGAAGAAdTdT-3’
5’-GGAUGGCUUUGAUGAGCUAdTdT-3’
5’-GGAGUAUUUCUUUAAGUAUdTdT-3’
5’-CCACAAUUCAGACCCACAAdTdT-3’
non-targeting siRNA 5’-UUCUCCGAACGUGUCACGUdTdT-3’
Table 2. Primer sequences used for reverse transcription (RT) PCR of the indicated 
genes. F - forward primer, R - reverse primer. 
mRNA NCBI accession no. Oligonucleotide sequence 
GAPDH-F BC083149 5’-ACGACCCCTTCATTGACCTCA-3’
GAPDH-R 5’-TTTGGCTCCACCCTTCAAGTG-3’
ASC (Pycard)-F NM_023258 5’-CTATCTGGAGTCGTATGGCTTG-3’
ASC (Pycard)-R 5’-CAGGTCCATCACCAAGTAGGG-3’
NLRC4-F NM_001033367 5’-CAGGTGGTCTGATTGACAGC-3’
NLRC4-R 5’-AAGCCTGCCGATCAGTTCCT-3’
NLRP3-F AY355340 5’-GCCTGTTCTTCCAGACTGGTG-3’
NLRP3-R 5’-TCTGGAGGTTGCAGAGCAGGT-3’
